[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369098":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":73,"collaborators":76,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":10,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":94,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Zhongshan People's Hospital, Guangdong, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening cohort",null,"30-69 years old healthy participants in Zhongshan and Wuzhou.",[13,14,15],"Biological: Blood and saliva","Diagnostic Test: P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA","Diagnostic Test: Fiberoptic endoscopy and biopsy",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"BIOLOGICAL","Blood and saliva","Collect blood and saliva samples from participants",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA","Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Fiberoptic endoscopy and biopsy","Screening participants will refer to fiberoptic endoscopy and biospy",[9],[32],{"name":33,"affiliation":5,"role":34},"Mingfang Ji, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","86-760-89880417","jmftbh@sina.com",[41,58],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Zhongshan People's Hospital","RECRUITING","Zhongshan","Guangdong","528403","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.37912,22.52306,{"lat":53,"lon":52},[56,57],{"name":33,"role":37,"phone":10,"phoneExt":10,"email":39},{"name":33,"role":34,"phone":10,"phoneExt":10,"email":10},{"facility":59,"status":43,"city":60,"state":61,"zip":62,"country":47,"countryCode":48,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Wuzhou Red Cross Hospital","Wuzhou","Guangxi","543002",{"type":50,"coordinates":64},[65,66],111.28848,23.48054,{"lat":66,"lon":65},[69,72],{"name":70,"role":37,"phone":10,"phoneExt":10,"email":71},"Yonglin Cai, MD","cylzen@hotmail.com",{"name":70,"role":34,"phone":10,"phoneExt":10,"email":10},{"type":34,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Mingfang Ji","Dr. Mingfang Ji",[77,78],{"name":59,"class":6},{"name":79,"class":6},"Xiamen University","100369098","screening-nasopharyngeal-carcinoma-with-ebv-associated-biomarkers-in-zhongshan-city-100369098",false,"NCT04085900","Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City","Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City","Inclusion Criteria:\n\n* Subject residents in Zhongshan City or Wuzhou City\n* Subject has no medical record of nasopharyngeal carcinoma\n* ECOG 0-2\n* Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.\n* Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study.\n\nExclusion Criteria:\n\n* Subject has heavy cardiovascular, liver or kidney disease.\n* Subject has contraindications to nasopharyngeal fiberoptic endoscopy.",true,"ALL","30 Years","69 Years",{"count":92,"type":93},40000,"ESTIMATED","5 Years","OBSERVATIONAL","All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually.\n\nAll subjects will also be followed by record linkage to Cancer Register and Population Register.",[98],"Nasopharyngeal Carcinoma",[100,98,101],"Screening","Biomarker","2023-07-12",{"date":104,"type":105},"2023-07-13","ACTUAL",{"date":107,"type":105},"2020-04-01",{"date":109,"type":93},"2027-12-31",{"name":5,"class":6},2]